20-F: Alps Group Inc. Faces Nasdaq Delisting Warning

Alps Group Inc. reported revenue growth but also disclosed a material weakness in internal controls and received a Nasdaq non-compliance notice regarding its share price.

Summary

• Alps Group Inc. filed its annual report on Form 20-F for the fiscal year ended March 31, 2026.
• The company reported a 44% increase in revenue to $4.86 million, driven by its medical testing, laboratory, and aesthetic beauty services, and cellular therapy segments.
• Despite revenue growth, the company incurred a net loss of $2.09 million for the fiscal year.
• A significant development is the company's receipt of a Nasdaq non-compliance notice for failing to maintain a minimum bid price of $1.00 per share, with a 180-day period to regain compliance.
• The filing also disclosed a material weakness in internal control over financial reporting, primarily related to insufficient accounting personnel and supervision.
• The company's R&D expenses decreased significantly, with a focus on NK cell therapy and MYCELEST.
• The company's financial position shows current liabilities exceeding current assets by $3.5 million, raising going concern considerations.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the company's ongoing net losses, material weakness in internal controls, and Nasdaq non-compliance, despite revenue growth.

Positives

• Revenue increased by 44% to $4.86 million for the fiscal year ended March 31, 2026.
• The medical testing, laboratory, and aesthetic beauty services segment grew by 20.3%.
• The cellular therapy segment saw a 51% revenue increase.
• Sales of medicine and healthcare products saw a substantial increase to $731,780.
• The company has a cGMP-compliant facility for cell therapy manufacturing.
• The company has a multidisciplinary team with expertise in scientific research, clinical trials, and manufacturing.

Negatives

• The company incurred a net loss of $2.09 million for the fiscal year ended March 31, 2026.
• A material weakness in internal control over financial reporting was identified.
• The company received a Nasdaq non-compliance notice regarding its minimum bid price, with a deadline to regain compliance.
• Current liabilities exceeded current assets by $3.5 million as of March 31, 2026.
• The company's product pipeline remains in the preclinical stage, with no regulatory approvals obtained.
• The company's share price was $0.4025 as of August 5, 2026, significantly below the $11.50 warrant exercise price.

Risks

• The company has limited operating history as a consolidated group and its product pipeline is in the preclinical stage.
• Failure to obtain substantial additional funding could compel the company to reduce its workforce or cease development of product candidates.
• The company's liquidity position is exposed to risks arising from near-term debt obligations.
• The company may not meet publicly announced product development objectives.
• The selection and prioritization of product candidates for development are subject to change, and abandoning a candidate could impact business prospects.
• The company faces challenges in developing manufacturing capabilities and relies on third-party manufacturers.
• Current product candidates are in preclinical development and may fail in clinical development or suffer delays.
• The company may be unable to secure trademark protection for the ALPS mark in Malaysia.

Future Outlook

The company expects to continue deriving revenues mainly from cellular therapy sales and medical testing, laboratory, and aesthetic beauty services while advancing its biotechnology pipeline. Management plans to expand service offerings into post-care for patients who have completed treatment. Additional financing may be sought through equity issuances, convertible notes, or strategic partnerships.

Management Comments

• "We expect to continue to derive our revenues mainly from cellular therapy sales and from the provision of medical testing, laboratory and aesthetics beauty services as we continue to advance our product candidates through and beyond the pre-clinical phase."
• "As a newly public company, Alps Group Inc. has limited operating history as a consolidated group, and investors have limited historical information upon which to evaluate our business, operations and prospects."
• "Alps will need to obtain substantial additional funding to complete the development of its product candidates."

Industry Context

StockSavvy.ai notes that Alps Group operates in the competitive biotechnology and healthcare sectors, with a focus on regenerative medicine and personalized healthcare. The company's strategy involves integrating commercial healthcare services with biotechnology research and development. The aesthetic and beauty care industry in Malaysia is also highly competitive, with established players having greater resources.

Comparison to Industry Standards

• The company's R&D expenses for FY2026 were $61,155, a significant decrease from FY2025 ($169,987) and FY2024 ($276,957), indicating a more focused R&D investment strategy.
• The company's gross margin was 32.1% in FY2026, compared to 38.6% in FY2025 and 24.9% in FY2024, with the change attributed to the revenue mix and profit-sharing arrangements in aesthetic services.
• The company's net loss narrowed to $2.09 million in FY2026 from $2.62 million in FY2025, an improvement attributed to revenue growth and non-cash gains, though the company remains in an investment phase.

Management Changes

Related Party Transactions

• Advances from Dr. Tham Seng Kong totaling $9,054,535.50 for working capital, with $6,137,372 outstanding as of March 31, 2026.
• Advances from Chew Yoke Ling totaling $127,781 for working capital, fully converted to shares.
• Management service agreements with various subsidiaries (Alpscap Berhad, Celebre Pro Medic Sdn. Bhd., Alps Wellness Centre Sdn. Bhd., Alps Globemedic Sdn. Bhd., Celetialab Sdn. Bhd., TMC Global Holdings Sdn. Bhd.) for management services.
• Patent License Agreements with Dr. Tham Seng Kong, Ding KeXiang, Yang Yong Peng, and Ding Yu, granting rights to patents related to stem cell and exosome processing technologies.

Stakeholder Impact

• Shareholders may face reduced value due to the Nasdaq non-compliance warning and the company's ongoing losses.
• Investors may be concerned about the material weakness in internal controls, potentially impacting financial reporting reliability.
• Employees may face uncertainty due to the company's financial position and potential need for further funding or restructuring.
• Creditors and suppliers may face risks related to the company's liquidity challenges and extended payment terms.

Next Steps

• Regain compliance with Nasdaq's minimum bid price requirement within 180 days (by November 11, 2026).
• Continue to advance product candidates through preclinical and clinical development stages.
• Expand commercial service offerings and laboratory business lines.
• Implement measures to remediate the identified material weakness in internal control over financial reporting.
• Explore opportunities for exosome-based therapeutic applications.
• Establish a Patient-Derived Organoid (PDO) laboratory and conduct related R&D activities.

Key Dates

Recommendation

The company's financial performance remains weak with significant net losses, a material weakness in internal controls, and a Nasdaq non-compliance warning regarding its share price. The preclinical stage of its product pipeline and the need for substantial additional funding present considerable risks. While revenue is growing, the path to profitability is uncertain, and the risk of delisting from Nasdaq is a significant concern for investors.

Keywords

biotechnology, cellular therapy, medical testing, aesthetic services, life sciences, clinical trials, Nasdaq, internal controls